Furthermore, patients with both anti-Ro52 and anti-Jo1 antibodies more frequently developed lung fibrosis and had more severe ILD compared with those with anti-Jo1 antibodies alone [43]. Here, TRIM21 is linked to pulmonary fibrosis.